IMA Wealth Inc. Sells 320 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IMA Wealth Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,967 shares of the biopharmaceutical company’s stock after selling 320 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.3% of IMA Wealth Inc.’s investment portfolio, making the stock its 27th biggest position. IMA Wealth Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,606,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of REGN. Private Trust Co. NA raised its position in Regeneron Pharmaceuticals by 30.4% during the 3rd quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 94 shares during the last quarter. CX Institutional raised its position in shares of Regeneron Pharmaceuticals by 10.7% in the 3rd quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 30 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 39.7% in the 3rd quarter. Ballentine Partners LLC now owns 996 shares of the biopharmaceutical company’s stock worth $820,000 after acquiring an additional 283 shares in the last quarter. Slow Capital Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.8% in the 3rd quarter. Slow Capital Inc. now owns 11,797 shares of the biopharmaceutical company’s stock worth $9,708,000 after acquiring an additional 208 shares in the last quarter. Finally, Valeo Financial Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 20.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock worth $509,000 after acquiring an additional 103 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $7.48 during trading on Friday, hitting $883.20. The stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average is $948.00 and its two-hundred day moving average is $893.63. The stock has a market cap of $96.94 billion, a price-to-earnings ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the business earned $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold 11,022 shares of company stock valued at $10,552,991 in the last 90 days. 8.83% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Barclays boosted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.